SCHEMBL15475795

SCHEMBL15475795

Cn1nc(O)c(-c2cc(F)cc(F)c2)c1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.41
MAPT P10636 1/20 0.38
POLB P06746 1/20 0.37
HRH4 Q9H3N8 1/20 0.33
KCNH2 Q12809 1/20 0.32
PIK3CD O00329 1/20 0.32
ABL1 P00519 1/20 0.32
EGFR P00533 1/20 0.32
HCK P08631 1/20 0.32
SRC P12931 1/20 0.32
KDR P35968 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
MTOR P42345 1/20 0.32
PIK3CG P48736 1/20 0.32
EPHB4 P54760 1/20 0.32
PRKDC P78527 1/20 0.32
PI4KB Q9UBF8 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15475705 0.87 KDM1A (0.36) MAPK14POLBPIK3CDSRCKDR
SCHEMBL6289612 0.77 MAPT (0.50) MAPK14MAPTPOLBSRCKDR
SCHEMBL15475895 0.77 ABL1 (0.40) MAPTPOLBABL1
SCHEMBL15475490 0.70 SMN1; SMN2 (0.50) MAPTPOLBPIK3CDABL1EGFR
SCHEMBL6292681 0.68 MAPT (0.49) MAPK14MAPTPOLBSRCADORA2A
SCHEMBL15813696 0.67 SMN1; SMN2 (0.41) MAPK14MAPTPOLBHRH4KCNH2
SCHEMBL1727252 0.64 MAPT (0.47) MAPK14MAPTPOLBADORA2A
SCHEMBL2955890 0.64
SCHEMBL31617234 0.63 KCNH2 (0.35) POLBKCNH2PIK3CDABL1EGFR
SCHEMBL1719539 0.63 MAPT (0.69) MAPK14MAPTPOLBSRCKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2885299-B1 INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A ABBVIE DEUTSCHLAND (DE) 2017-04-05 EP disclosed
US-9464085-B2 Inhibitor compounds of phosphodiesterase type 10A AbbVie Deutschland GmbH & Co. KG (DE) 2016-10-11 US disclosed
EP-2885299-A1 INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A AbbVie Deutschland GmbH & Co KG (DE) 2015-06-24 EP disclosed
WO-2014027078-A1 INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A AbbVie Deutschland GmbH & Co. KG (DE) 2014-02-20 WO disclosed
US-20140051695-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A AbbVie Deutschland GmbH & Co. KG (DE) 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051695-A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A PDE3A, PDE5A, PDE7A MAPK14 2665/4885MAPT 1238/4885POLB 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.